Related Experiment Video
Updated: Oct 2, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
[Mitral valve prolapse, arrhythmias and sudden death]
J P Fauchier1, D Babuty, L Fauchier
1Service de cardiologie B et laboratoire d'électrophysiologie cardiaque, CNRS UMR 6542, hôpital Trousseau, 37044 Tours.
Abstract:
Some of the classical concepts of mitral valve prolapse (MVP) should be reviewed in the light of recent publications. It is a condition, according to strict echocardiographic criteria excluding near physiological abnormalities, which affects 2 to 3% of the adult population in the industrialised world. Only repetitive atrial arrhythmias and complex ventricular arrhythmias are more common in this condition than in control groups, the differences being more pronounced in cases of mitral regurgitation. The risk of syncope or sudden death is 0.1% per year, hardly any different to that of the rest of the general adult population (0.2%). However, this risk may attain 0.9 to 2% in cases with mitral regurgitation. The causes of sudden death are unclear (haemodynamic, neurohumoral, arrhythmic, etc...), although there is evidence in favour of malignant ventricular arrhythmias. Detailed clinical, electrophysiological, isotopic and anatomopathological studies have raised doubts as to the direct responsibility of the vascular malformation (or its eventual consequences on the atrial and ventricular chambers) in this mode of fatal outcome. On the other hand, localised or diffuse myocardial disease is often observed, usually a- or pauci-symptomatic, associated with MVP, the responsibility of which is more plausible. Therefore, the physician should adopt a flexible attitude towards these patients, reassuring those with benign symptoms at low risk and following up or actively treating the rarer malignant forms (especially familial, syncopal with mitral regurgitation and/or severe arrhythmias).
Insights
Mitral valve prolapse (MVP) affects 2-3% of adults. While generally low risk, severe MVP with mitral regurgitation can increase risks of sudden death, suggesting myocardial disease over valve issues.
Area of Science:
- Cardiology
- Valvular Heart Disease
Context:
- Mitral valve prolapse (MVP) is a common valvular condition.
- Recent publications necessitate a review of MVP concepts.
- Strict echocardiographic criteria define MVP, affecting 2-3% of the adult population.
Purpose:
- To review classical concepts of mitral valve prolapse (MVP) in light of recent publications.
- To clarify the risks associated with MVP, particularly regarding arrhythmias and sudden death.
- To differentiate between direct valvular malformation and myocardial disease as causes of adverse outcomes.
Summary:
- MVP affects 2-3% of adults; arrhythmias are more common, especially with mitral regurgitation.
- Sudden death risk is low (0.1% annually) but higher (0.9-2%) with mitral regurgitation.
- Myocardial disease, often asymptomatic, is increasingly implicated in fatal MVP outcomes, rather than the valve malformation itself.
Impact:
- Physicians should adopt a flexible approach to MVP patient management.
- Low-risk patients with benign symptoms require reassurance.
- High-risk patients, especially those with familial history, syncope, mitral regurgitation, or severe arrhythmias, need close monitoring and active treatment.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation I: Introduction
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Stenosis I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests

